Buscar en
Angiología
Toda la web
Inicio Angiología Arteriopatía periférica, tratamientoy cumplimiento
Journal Information
Vol. 55. Issue 3.
Pages 217-227 (January 2003)
Share
Share
Download PDF
More article options
Vol. 55. Issue 3.
Pages 217-227 (January 2003)
Full text access
Arteriopatía periférica, tratamientoy cumplimiento
Treatment and compliance of peripheralarteriopathy
Arteriopatia periférica, tratamento eadesão
Visits
2856
S. Cancer-Pérez
Corresponding author
scancer@fhalcorcon.es

Correspondencia: Fundación Hospital Alcorcón. Budapest, 1. E-28922 Alcorcón (Madrid).
, S. Luján-Huertas, E. Puras-Mallagray, M. Gutiérrez-Baz
Servicio de Angiología y Cirugía Vascular. Fundación Hospital Alcorcón. Alcorcón, Madrid, España.
This item has received
Article information
Resumen
Objetivos

Evaluar el cumplimiento del tratamiento antiagregante con clopidogrel en pacientes con claudicación intermitente, analizar los factores de riesgo (FR) clásicos y su control en el tiempo y evaluar la correlación del test de elevación de tobillo y la claudicometría, el conocimiento de la enfermedad por parte delpaciente y la evolución de la calidad de vida.

Pacientes y métodos

Serealizó un estudio epidemiológico, de observación, prospectivo y multicéntrico. Se incluyeronpacientes con claudicación intermitente y elseguimiento fue de 6meses. a cadapaciente se le realizó: índice tobillo/brazo, claudicometríay test de elevación del tobillo, test de cumplimiento autocomunicado de Haynes-Saccket, cuestionario de Batalla, cuestionario de salud SF-12, índice de actividad de Duke y analítica, en cada visita. Las variables se analizaron mediante el test χ2, test F-Fisher, y testsigned-rank para datos pareados. Se consideraron estadísticamente significativos valores de p> 0,05.

Resultados

De los 928 pacientes incluidos, completaron las tres visitas 372. El cumplimiento del tratamiento fue del 98,5%. A los 6 meses, tan sólo el 20,8% de los pacientes conocían la enfermedad, y el único FR que mejoró fue el tabaquismo (p= 0,04). La calidad de vida disminuía con relación a la población general. El test de elevación del tobillo y la claudicometría mostraron una correlación significativa (Pearson= 0,84).

Conclusiones

Apesar de que elcumplimiento deltratamiento es muy elevado, la mayoría de los pacientes con claudicación intermitente no tienen un conocimiento preciso de su enfermedad.El control de los FR tras 6 meses de seguimiento no es adecuado.

Palabras clave:
Calidadde vida
Claudicación intermitente
Claudicometría
Cumplimiento
Factores de riesgo
Test de elevación de tobillo
Summary
Aims

The aim of this study was to evaluate clopidogrel antiaggregant therapy compliance in patients with intermittent claudication. We also sought to analyse the classical riskfactors (RF) and their control over time, and to evaluate the correlation of the ankle-raising test and treadmill exercise testing, the patient's knowledge of the disease and how quality of life progresses.

Patients and methods

We conducted aprospective, multicentre epidemiological study based on observation. The sample was made up of patients with intermittent claudication, who were monitored over a 6-month period. Each patient was submitted to the following tests: Ankle-Brachial lndex, treadmill exercise testing and ankle-raising test, Haynes-Sackett self-reported compliance test, the Batalla survey, the SF-12 health survey, the Duke activity index and analyses on each visit. The variables were analysed by means of the chi-squared test, Fisher's F test, and Signed-rankfor paired data test. Values of p < 0.05 were considered to be statistically significant.

Results

Of the 928 patients included in the study, 372 completed the three visits. Therapy compliance was 98.5%. At six months only 20.8% of the patients knew the disease and the only RF that improved was smoking (p= 0.04). Quality of life diminished in relation to the general population. The ankle-raising test and treadmill exercise testing showed a significant correlation (Pearson= 0.84).

Conclusions

Although therapy compliance is very high, most patients with intermittent claudication do not have accurate knowledge of the disease they are suffering from. After 6 months'follow-up, the control of RF is not adequate.

key words:
Ankle-raising test
Compliance
Intermittent claudication
Quality of life
Risk factors
Treadmill exercise testing
Resumo
Objectivos

Avaliar a adesão ao tratamento antiagregante com clopidogrel em doentes com claudicação intermitente. Analisar os factores de risco (FR) clássicos e seu controlo no tempo, avaliar a correlação do teste de elevação do tornozelo e claudicometria, o conhecimento da doençapor parte do doente e a evolução da qualidade de vida.

Doentes e métodos

Estudo epidemiológico, de observação, prospectivo e multicêntrico. Foram incluídos doentes com claudicação intermitente e o seguimento foi de 6 meses. Em cada doente realizou-se: índice tornoze-lo/braço, claudicometria e teste de elevação do tornozelo, teste de adesão autocomunicada de Haynes-Saccket, questionário de Batalla, questionário de saúde SF-12, índice de actividade de Duke e analítica em cada visita. As variáveis foram analisadas pelo teste do chi-quadrado, teste F-Fisher e teste Signed-rank para dados emparelhados. Consideraram-se estatisticamente significativos valores de p < 0,05.

Resultados

Dos 928 doentes incluídos, completaram as três visitas 372. A adesão ao tratamento foi de 98,5%. Aos seis meses, apenas 20,8% dos doentes conheciam a doença e o único FR que melhorou foi o tabagismo (p= 0,04). A qualidade de vida diminuía em relação àpopulação em geral. O teste de elevação do tornozelo e a claudicometria mostraram uma correlação significativa (Pearson= 0,84).

Conclusões

Apesar da adesão ao tratamento ser muito elevado, a maioria de doentes com claudica-ção intermitente não têm um conhecimento preciso da sua doença. O controlo dos FR aos 6 meses de seguimento não é adequado.

Palavras chave:
Adesão
Claudicação intermitente
Claudicometria
Factores de risco
Qualidade de vida
Teste de elevação do tornozelo
Full text is only aviable in PDF
Bibliografía
[1.]
TransAtlantic Inter-Society Consensous (TASC).
Management of peripheral arterial disease (PAD).
J Vasc Surg., 31 (2000), pp. 5-85
[2.]
Dormandy J..
Fate of the patient with chronic leg ischaemia.
J Cardiovasc Surg., 30 (1989), pp. 50-57
[3.]
Dormandy J., Heeck L., Vig S..
The natural history of claudication: risk to life and limb.
Semin Vasc Surg., 12 (1999), pp. 123-137
[4.]
Donnelly R., Yeung J.M.C..
Management of intermittent claudication: the importance of secondary prevention.
Eur J Vasc Endovasc Surg., 23 (2002), pp. 100-107
[5.]
Schmiender F.A., Comerota A.J..
Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies.
Am J Cardiol, 87 (2001), pp. 3-13
[6.]
Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet theraphy in various categories of patients. Antiplatelet Trialists' Collaboration.
BMJ, 308 (1994), pp. 81-106
[7.]
The CAPRIE Steering Committee.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events.
Lancet, 348 (1996), pp. 1329-1339
[8.]
Pell J.P..
Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group.
Eur J Vasc Endovasc Surg., 9 (1995), pp. 469-472
[9.]
Khaira H.S., Hanger R., Shearman C.P..
QOL in patients with intermittent claudication.
Eur J Vasc Endovasc Surg., 11 (1996), pp. 65-69
[10.]
Klevsgard R., Hallberg I.R., Risberg B., Thomsen M.B..
Quality of life associated with varying degrees of chronic lower limb ischaemia: comparison with a healthy sample.
Eur J Vasc Endovasc Surg., 17 (1999), pp. 319-325
[11.]
Hicken G.J., Lossing A.G., Ameli F.M..
Assessment of generic health-related quality of life in patients with intermittent claudication.
Eur J Vasc Endovasc Surg., 20 (2000), pp. 336-341
[12.]
Breek J.C., Hamming J.F., De Vries J., Aquarius A.E.A.M., van Berge-Henegouwen D.P..
Quality of life in patients with intermittent claudication using the world health organisation (WHO) questionnaire.
Eur J Vasc Endovasc Surg., 21 (2001), pp. 118-122
[13.]
Breeck J.C., Hamming J.F., De Vries J., Aquarius A.E.A.M., van Berge-Henegouwen D.P., van Heck G.L..
The impact of walking impairment, cardiovascular risk factors, and comorbidity on quality of life in patients with intermittent claudication.
J Vasc Surg., 36 (2002), pp. 94-99
[14.]
Sackett D.L., Haynes R.B., Fuyatt G.H., Tungwell P..
Ayudar a los pacientes a cumplir los tratamientos.
Epidemiología clínica. Ciencia básica para la medicina clínica, 2, pp. 249-278
[15.]
Batalla C., Blanquer A., Ciurana R., García M., Cases E.J., Pérez A., et al.
Cumplimiento de la prescripción farmacológica en pacientes hipertensos.
Aten primaria, 1 (1984), pp. 185-191
[16.]
Beattie D.K., Golledge J., Greenhalgh R.M., Davies A.H..
Quality of life assessment in vascular disease: towards a consensus.
Eur J Vasc Endovasc Surg., 13 (1997), pp. 9-13
[17.]
Chetter I.C., Spark J.I., Dolan P., Scott D.J.A., Kester R.C..
Quality of life analysis in patients with lower limb ischaemia: suggestions for european standardisation.
Eur J Vasc Endovasc Surg., 13 (1997), pp. 597-604
[18.]
Alonso J., Prieto L., Antó J.M..
La versión española del SF-36 Health Survey (cuestionario de salud SF-36): Un instrumento para la medida de los resultados clínicos.
Med Clin, 104 (1995), pp. 771-776
[19.]
Alonso J., Regidor E., Barrio G., Prieto L., Rodríguez C., de la Fuente L..
Valores poblacionales de referencia de la versión española del Cuestionario de Salud SF-36.
Med Clin, 111 (1998), pp. 410-416
[20.]
Hlatky M.A., Boineau R.E., Higginbotham M.B., Lee K.L., Mark D.B., Califf R.M., et al.
A brief self-administered questionnaire to determine functional capacity (The Duke activity status index).
Am J Cardiol, 64 (1989), pp. 651-654
[21.]
Alonso J., Permanyer-Miralda G., Cascant P., Brotons C., Prieto L., Soler-Soler J..
Measuring functional status of chronic coronary patients. Reability, vality and responsiveness to clinical change of the reduced version of the Duke Activity Status Index (DASI).
Eur Heart J, 18 (1997), pp. 414-419
[22.]
Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al.
Mortality over a period of 10 years in patients with peripheral arterial disease.
N Engl J Med., 326 (1992), pp. 381-386
[23.]
Eagle K.A., Rihal C.S., Foster E.D., Mickel M.C., Gersh B.J..
Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease.
J Am Coll Cardiol, 23 (1994), pp. 1091-1095
[24.]
Regensteiner J.G., Hiatt W.R..
Current medical therapies for patients with peripheral arterial disease: a critical review.
Am J Med., 112 (2002), pp. 29-57
[25.]
Hirsch A.T., Criqui M.H., Treat-Jacobson D., Regensteiner J.G., Creager M.A., Olin J.W., et al.
Peripheral arterial disease detection, awareness, and treatment in primary care.
JAMA, 286 (2001), pp. 1317-1324
[26.]
Mukherjee D., Lingam P., Chetcuti S., Grossman M., Moscucci M., Luciano A.E., et al.
Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions. Insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI).
Circulation, 106 (2002), pp. 1909-1912
[27.]
Piñeiro F., Gil V., Donis M., Orozco D., Pastor R., Merino J..
Validez de 6 métodos indirectos para valorar el cumplimiento del tratamiento farmacológico en la hipertensión arterial.
Aten primaria, 19 (1997), pp. 372-375
[28.]
Sackett D.L., Haynes R.B., Gibson E.S., Hackett B.C., Taylor D.W., Roberts R.S., et al.
Randomised clinical trial of strategies for improving medication compliance in primary hypertension.
Lancet, 1 (1975), pp. 1205-1207
[29.]
Amirhamzeh M.M.R., Chant H.J., Rees J.L., Hands L.J., Powell R.J., Campbell W.B..
A comparative study of treadmill test and heel raising exercise for peripheral arterial disease.
Eur J Vasc Endovasc Surg., 13 (1997), pp. 301-305
[30.]
Rutherford R.B., Baker J.D., Ernst C., Johnston K.W., Porter J.M., Ahn S., et al.
Recommended standards for reports dealing with lower extremity ischemia: revised version.
J Vasc Surg., 26 (1997), pp. 517-538
[31.]
Chetter I.C., Scott D.J.A., Kester R.C..
An introduction to quality of life analysis: the outcome measure in vascular surgery.
Eur J Vasc Endovasc Surg., 15 (1998), pp. 4-6
[32.]
Golledge J., Garrat A., Greenhalgh R.M., Davies A.H..
Patient-assessed health outcome in peripheral arterial disease.
Eur J Vasc Endovasc Surg., 19 (2000), pp. 109-110
Copyright © 2003. SEACV
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos